A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
NCT07383506 · NOT YET RECRUITING · Phase 1
ReadTheTrial indexes 1 studies for Pik3ca Mutations. The most common development stage is Phase 1 (1 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.
1 clinical trials found for Pik3ca Mutations.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
There are 1 clinical trials listed for Pik3ca Mutations. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.
Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.
Current Pik3ca Mutations trials are distributed across: Phase 1 (1).